What is the current size of the blood based biomarkers market?

The market valuation of the blood based biomarkers is USD 9.85 billion in 2027.

What are the growth projections for the blood based biomarkers industry?

Blood Based Biomarkers Market size was worth USD 9.3 billion in 2026 and is expected to grow at a 7.03% CAGR between 2027 and 2036, reaching USD 18.35 billion by 2036.

How is rising chronic disease prevalence influencing adoption of blood-based biomarkers in early diagnosis?

Increasing cardiovascular and chronic disease burden is expanding use of blood-based biomarkers for early detection and monitoring. Healthcare systems rely on them for risk stratification, enabling earlier intervention and reducing dependence on invasive diagnostic procedures.

How are NGS and liquid biopsy advancements reshaping clinical adoption of blood-based biomarkers?

Improved sequencing sensitivity and liquid biopsy tools are increasing clinical confidence in blood-based testing. These advances support non-invasive detection, treatment selection, and routine integration into diagnostics and disease monitoring workflows.

Why do hospitals and clinics lead the blood based biomarkers market?

Hospitals & Clinics held a 49.72% share in 2026 because biomarker testing is integrated into routine diagnosis, disease monitoring, and physician-led treatment planning, supported by high patient volumes and established care pathways.

Why are diagnostic laboratories the fastest-growing end-use segment in the blood based biomarkers market?

Diagnostic laboratories are expanding rapidly as demand grows for specialized testing, efficient sample processing, broader test menus, and scalable workflows that support increasing biomarker-based screening and monitoring requirements.

Why does North America dominate the blood based biomarkers market?

North America holds 45.35% share, driven by advanced clinical testing infrastructure, precision medicine adoption, and strong integration of biomarker diagnostics across oncology, neurology, and cardiovascular care.

How is Asia Pacific driving growth in blood based biomarkers?

Asia Pacific expands at 8.25% CAGR, supported by rising diagnostic demand, expanding healthcare access, and growing adoption of scalable blood-based testing across large patient populations.

Who are the leading players in the blood based biomarkers landscape?

Major companies in the blood based biomarkers market include Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (United States), bioMérieux SA (France), Bio-Rad Laboratories Inc. (United States), Sysmex Corporation (Japan), Danaher Corporation (United States), QuidelOrtho Corporation (United States), Illumina Inc. (United States).